Africa: dependable supply of HIV testing reagents needed for crucial early stage TB/HIV testing
This article was originally published in Clinica
Executive Summary
Lack of a regular supply of HIV testing reagents is hindering the progress of an integrated TB/HIV testing programme in Malawi. The problem is highlighted in a review of a 2003-2005 HIV testing plan recently published in The International Journal of Public Health 2007 (Bulletin of the World Health Organization). Despite this setback, the initiative's effort to scale up HIV testing for TB and HIV-positive TB patients (one among several objectives) was successful, achieving an increase in HIV tests from 15% in 2003 to 47% in 2005.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.